Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Stay up-to-date on Wall Street's latest analyst calls, stock downgrades, and upgrades for major companies like Sarepta, Cisco, and more.

Both patients were teenage boys who passed away after developing acute liver failure within two months after treatment with Sarepta’s one-time therapy.

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics SRPT, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Today's biotech news features an FDA probe into the deaths tied to Sarepta's Duchenne drug, rejecting KalVista's drug application, etc.

Review Sarepta Therapeutics Inc (1SRPT:XMIL) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, TD Cowen downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT ...